Search Results - "Magnani, Ottavia"

  • Showing 1 - 16 results of 16
Refine Results
  1. 1

    Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? by Murdaca, Giuseppe, Spanò, Francesca, Contatore, Miriam, Guastalla, Andrea, Penza, Elena, Magnani, Ottavia, Puppo, Francesco

    Published in Expert opinion on drug safety (02-01-2016)
    “…TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying antirheumatic drugs (DMARDs) in the treatment of…”
    Get more information
    Journal Article
  2. 2

    From sciatica pain to a complex diagnosis: a case of pyomyositis and chronic lymphocytic leukemia by Magnani, Ottavia, Caiti, Matteo, Cenni, Elisabetta, Moscatelli, Paolo

    Published in Italian journal of medicine (27-09-2021)
    “…We described a case of a 50-year-old man who presented severe low back and leg pain that quickly evolved in severe septic shock. Clinical workouts led us to…”
    Get full text
    Journal Article
  3. 3

    Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis by Murdaca, Giuseppe, Negrini, Simone, Magnani, Ottavia, Penza, Elena, Pellecchio, Marco, Gulli, Rossella, Mandich, Paola, Puppo, Francesco

    Published in Modern rheumatology (01-05-2018)
    “…TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of…”
    Get full text
    Journal Article
  4. 4

    Defective expression and function of the leukocyte associated Ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients by Colombo, Barbara M, Canevali, Paolo, Magnani, Ottavia, Rossi, Edoardo, Puppo, Francesco, Zocchi, Maria Raffaella, Poggi, Alessandro

    Published in PloS one (15-02-2012)
    “…Systemic lupus erythematosus (SLE) is characterized by the production of a wide array of autoantibodies and dysregulation of B cell function. The leukocyte…”
    Get full text
    Journal Article
  5. 5

    Successful treatment with belimumab of severe systemic lupus erythematosus not responding to standard therapy: a case report by Magnani, Ottavia, Penza, Elena, Murdaca, Giuseppe, Puppo, Francesco

    Published in Clinical management issues (31-03-2016)
    “… Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by complex pathophysiology and heterogeneous clinical picture. Belimumab is the…”
    Get full text
    Journal Article
  6. 6

    Infection risk associated with anti-TNF-α agents: a review by Murdaca, Giuseppe, Spanò, Francesca, Contatore, Miriam, Guastalla, Andrea, Penza, Elena, Magnani, Ottavia, Puppo, Francesco

    Published in Expert opinion on drug safety (01-04-2015)
    “…TNF-α is a pro-inflammatory cytokine known to a have a key role in the pathogenesis of chronic immune-mediated diseases. TNF-α inhibitors can be administered…”
    Get more information
    Journal Article
  7. 7
  8. 8

    HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact by Murdaca, Giuseppe, Calamaro, Paola, Lantieri, Francesca, Pigozzi, Simona, Mastracci, Luca, Grillo, Federica, Magnani, Ottavia, Ceppa, Paola, Puppo, Francesco, Fiocca, Roberto

    “…To analyze expression of human leukocyte antigen-G (HLA-G) in gastric adenocarcinoma and correlate its expression with histological and clinical variables. A…”
    Get full text
    Journal Article
  9. 9

    Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy by Murdaca, Giuseppe, Spanò, Francesca, Contatore, Miriam, Guastalla, Andrea, Magnani, Ottavia, Puppo, Francesco

    “…During the last decade, many new biological immune modulators have entered the market as new therapeutic principles. Biologics, including TNF-α inhibitors, are…”
    Get more information
    Journal Article
  10. 10

    Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis by Murdaca, Giuseppe, Negrini, Simone, Magnani, Ottavia, Penza, Elena, Pellecchio, Marco, Puppo, Francesco

    Published in Expert opinion on drug safety (03-10-2017)
    “…TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of…”
    Get more information
    Journal Article
  11. 11
  12. 12

    Efficacy and safety of etanercept in chronic immune-mediated disease by Murdaca, Giuseppe, Spanò, Francesca, Contatore, Miriam, Guastalla, Andrea, Magnani, Ottavia, Puppo, Francesco

    Published in Expert opinion on drug safety (01-05-2014)
    “…TNF-α inhibitors have demonstrated efficacy in large, randomized controlled clinical trials either as monotherapy or in combination with other…”
    Get more information
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16